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Abstract 
The burden of influenza in Africa is significant and under-appreciated. While surveillance has 
increased, our understanding of seasonal influenza vaccine performance remains limited. We 
conducted a systematic review, using PRISMA guidelines (PROSPERO CRD42017058107), on the 
efficacy, effectiveness and immunogenicity of influenza vaccines in populations within Africa with 
the aim of identifying key data gaps to help direct future research. We searched Embase, 
Medline, Global Health and Web of Science for published studies from database inception to May 
9th, 2018. Unpublished studies were identified by searching ClinicalTrials.gov and the Pan-African 
Clinical Trial Registry and by contacting experts within the field. Human studies which reported 
influenza vaccine immunogenicity, effectiveness and efficacy were included. The quality of each 
study was assessed using the GRADE framework. 1746 articles were assessed and 23 articles 
included: six maternal immunisation, 6 child immunisation, three elderly immunisation and 8 
other articles. Only three studies were of high quality and many studies were under-powered. All 
studies came from only six African countries (16 from South Africa), highlighting the need for 
data from a broader range of African populations. The majority of studies focused on 
effectiveness or efficacy against laboratory confirmed influenza with limited data on severe 
outcomes.  Several factors known to interfere with influenza immunization, such as malaria, HIV 
and malnutrition were under-represented in this review and require further study.  Significant 
gaps exist in our understanding of influenza vaccine performance across all WHO high risk groups 
in Africa.  
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The impact of influenza on African populations and health systems is under-appreciated. Influenza 
causes approximately 300,000-650,000 deaths per year with the highest mortality rates seen in 
sub-Saharan Africa.1 The per capita influenza-associated hospitalisation rate in children <5 years is 
estimated to be 174 per 100,000/year in Africa compared to 53 per 100,000/year in Europe.2 
Influenza surveillance in 15 African countries (2006 – 2010) showed the overall proportion of 
influenza positivity was 21·7% in influenza-like illness (ILI) cases and 10·1% in severe acute 
respiratory infection (SARI).3 A combination of poor nutrition and socioeconomic conditions, 
higher prevalence of co-infections (E.g. HIV, tuberculosis, Streptococcus pneumoniae) and limited 
access to healthcare, may contribute to seasonal influenza infections playing a greater role in 
respiratory disease-related morbidity and mortality in Africa than in high income countries (HIC).4  
 
In 2012, the WHO Strategic Advisory Group of Experts recommended influenza vaccination 
programmes focusing on key high-risk groups:5 pregnant women, children aged 6–59 months, 
individuals with specific chronic illnesses, the elderly and health care workers. Despite these 
recommendations, by 2014, only three African countries (of 47 WHO member states) had seasonal 
influenza vaccine policies: South Africa, Algeria and Morrocco.6 While the reasons for this are 
multifactorial (including health economic), there is a lack of knowledge regarding influenza vaccine 
performance in African populations and no systematic review has been published. Previous 
examples such as rotavirus and oral polio vaccines show that efficacy and immunogenicity data 
from HIC are not always transferrable to low and middle-income countries (LMICs).7 Several factors 
such as year-round transmission of influenza within the tropics,8 high HIV prevalence and reduced 
maternal antibody transfer with malaria infection9 could influence vaccine performance. We have 
carried out a systematic review of the current literature to identify key data gaps in the efficacy, 
effectiveness and immunogenicity of influenza vaccines in African populations and help shape 
future research priorities. 
 
Methods 
The study was conducted using PRISMA guidelines and registered with PROSPERO 
(CRD42017058107). 
Search strategy and selection criteria 
Published articles were identified by searching Embase, Medline, Global health and Web of Science 
using the following strategy: (influenza OR flu) AND (vaccin* OR immuni#ation OR Influenza 
Vaccines [Subject heading]) AND (effic* OR effect* OR immune* OR respons* OR protect*) AND 
(Africa OR Africa [Subject heading] OR each African country [defined by United Nations]). A full list 
of included countries is shown in the Appendix. Databases were first search on the 17th of January 
2017 and an updated search carried out on the 9th of May 2018. Unpublished trials were identified 
by searching Clinicaltrials.gov and the Pan-African Clinical Trial Registry. Experts within the field 
were contacted. References within identified studies were reviewed for additional articles. All 
studies which assessed influenza vaccine efficacy, effectiveness or immunogenicity (definitions 
below) in populations within African countries, were included. No studies were excluded based on 
year, language or quality. Purely descriptive observational studies were excluded, as were animal 
immunogenicity studies.  
 
Definitions, data extraction and quality assessment 
Vaccine efficacy is defined as a relative reduction in influenza risk after vaccination determined by 
a randomised controlled trial (RCT). Effectiveness denotes a relative reduction in odds of influenza 
associated with vaccination in an observational study. Immunogenicity is used to mean the 
immune response to influenza vaccination. Two authors (BL and EPA) carried out the following 
methods independently. Titles and abstracts were screened for relevance. Full articles were 
reviewed against inclusion and exclusion criteria. Data from included trials were extracted: 
population, design/methodology, participant numbers, type of vaccine, and key findings (vaccine 
efficacy/effectiveness with confidence intervals and/or haemagglutination inhibition titres). Data 
were inputed into a table created in Microsoft Word. Vaccine efficacy or effectiveness studies were 
grouped and evaluated as per WHO high risk groups.5 Immunogenicity outcomes were summarised 
together. The limitations and quality of each study were assessed using the GRADE framework10 
and used to identify populations lacking high quality studies. Discrepancies with data extraction 
and quality assessment were settled by discussion and consensus. A meta-analysis would be 
carried out if greater than two studies from the same WHO high risk group5 were identified which 
shared similar populations, interventions, comparison and outcomes. 
 
Results 
Study selection and characteristics 
Titles and abstracts of 1746 published articles were screened (Figure 1) and 68 full-text articles 
were assessed for eligibility. Of these, studies were excluded due to a lack of efficacy, effectiveness 
or immunogenicity data (23), presence of duplicate data (18), data from a non-African country (1) 
and lack of influenza vaccine usage (3). 23 studies were included (Supplementary table 1).11-33  
Studies varied by study design, vaccine type (inactivated influenza vaccine, IIV3; live attenuated 
influenza vaccine, LAIV) and study population (Table 1).  16 were from South Africa,11-14,16-19,23,25,27-
32 two each from Gabon21,22 and Kenya,20,26 and one study each from Mali15,33 Senegal24 and The 
Gambia.33 The following study populations were identified: pregnant women (6 studies), children 
(6), elderly (3), HIV-Positive adults (1), healthcare workers (1) and all age groups (6). Study design 
included RCTs (12 studies), case-control studies (6), and cohort studies (1). Vaccines used included 
IIV3 (17 studies),  LAIV (3), both IIV3 and LAIV (2) and a monovalent inactivated pandemic H1N1 
vaccine (1). Articles were evaluated in detail after grouping by WHO high-risk population.5 A 
summary of vaccine efficacy and effectiveness from each study is shown in figure 2. A meta-
analysis was deemed unsuitable due to the low number of studies sharing a similar population, 
intervention, comparison and outcome. 
 
Influenza vaccination in pregnant women 
One RCT from South Africa11 and one from Mali15 evaluated influenza vaccination in pregnant 
women, with three studies reporting secondary analyses from the South Africa RCT12-14 and one 
study reporting a secondary analysis from both RCTs (Supplementary table 1).31 A single centre, 
randomised, double-blind placebo-controlled trial including HIV-uninfected and HIV-infected 
pregnant women (60% on HAART at enrolment, median CD4 count 393·5 cells/mm3) was 
conducted in South Africa.11 The influenza attack rate in HIV-infected placebo recipients was higher 
than in HIV-uninfected placebo recipients (17·0% vs to 3·5%). The per-protocol vaccine efficacy 
against all reverse transcriptase polymerase chain reaction (RT-PCR)-confirmed symptomatic 
influenza was 54.4% (95% CI 19·5, 74·2, P=0.005) for HIV-uninfected women and 70·6% (95% CI 
23·0, 88·8, P=0·02) for HIV-infected women. Infants born to HIV-uninfected women had a per-
protocol vaccine efficacy against RT-PCR-confirmed symptomatic infection of 45·6% (95% CI 2·4, 
69·7, P = 0·04) at six months of age compared to 42·3% (95% CI -96·9, 83·1, P=0·52) in HIV-exposed-
uninfected infants. No impact of vaccination on birthweight, clinical febrile illness or ILI was seen, 
although the study was not powered for these outcomes. 
 
An extended follow up study12 of the HIV-uninfected women failed to show statistically significant 
protective efficacy against RT-PCR-confirmed symptomatic influenza during the following season. 
No power calculation for vaccine efficacy in the extended period was reported, which included 
only a subset of participants. A secondary analysis of the HIV-unexposed infants showed that 
vaccine efficacy against RT-PCR-confirmed symptomatic influenza was 53·9% (95% CI 10·4, 77·4, 
P=0·02) at ≤16 weeks of age, with no statistically significant protection at >16–24 weeks.13 A further 
analysis of the HIV-unexposed infants demonstrated that maternal immunisation reduced 
hospitalisation for all-cause acute lower respiratory infection (ALRI) by 57·5% (95% CI 7·0, 81·0, 
P=0·032) during the first 90 days of life.14 The vaccine efficacy against severe infant pneumonia 
over the first 180 days of life was 43% (95% CI 0, 67, p=0·05).31 
 
Results from a multicentre, active-controlled, observer-blind RCT in HIV-uninfected pregnant 
women conducted in Mali15 showed similar results. The vaccine efficacy against all RT-PCR-
confirmed symptomatic influenza was 76·6% (95% CI 28·4, 94·8) for women during pregnancy and 
70·1% (95% CI 28·0, 89·1) in the six-month post-partum period. Cumulative per-protocol vaccine 
efficacy against all RT-PCR-confirmed symptomatic influenza in infants was 70·2% (95% CI 11·3, 
91·1) during the first four months, decreasing to 37·3% (95% CI 7·6, 57·8) by six months of age. No 
difference was seen in the birthweights between vaccine groups, although the study was not 
powered for this outcome. A secondary analysis of this trial reported a vaccine efficacy against all-
cause severe infant pneumonia in the first 180 days of life of -17% (95% CI -67, 19, P=0.39).31 
 
Influenza vaccination in children 
Four studies were identified which reported vaccine efficacy (3) or effectiveness (1) of influenza 
vaccination in children (Supplementary table 1).19,20,23,24 A multicentre, double-blind, placebo-
controlled RCT in healthy children aged 6 to <36 months from South Africa, Brazil, and Argentina23 
investigated the efficacy of LAIV (Ann-Arbor backbone, Medimmune). Data from the South African 
participants (n=277) was obtained via personal communication with authors of a meta-analysis 
analysing country-stratified data (Christopher Ambrose, personal communication).34 This data 
generated an efficacy estimate for two LAIV doses of 87% (95% CI 64, 95) for prevention of culture-
confirmed symptomatic influenza in South Africa. There are no country-stratified demographic 
data available on factors such as nutritional status or ethnicity, which may be important to assess 
the generalisability of these findings to other African populations.  
 The efficacy of one dose of Russian-backbone LAIV (Nasovac-S®, Serum Institute of India Pvt Ltd) 
among healthy children in Senegal aged 2 to 5 years was reported recently.24 This single centre, 
randomised, double-blind, placebo-controlled study was designed assuming a 6% influenza 
incidence. Per-protocol vaccine efficacy was 0.0% (95% CI -26·4, 20·9) for all influenza strains and 
-6.1% (95% CI -50.0, 25.0) for all vaccine-matched strains (78·2% were pdm09H1N1) against RT-
PCR-confirmed symptomatic influenza. The overall attack rate was 18% and vaccine-matched 
strain attack rate 8–9%. Most vaccine-unmatched isolates were influenza B (Victoria lineage) 
viruses. The absence of immunogenicity measurements to investigate the lack of efficacy observed 
was a major limitation of this study.  
 
Madhi et al. (2013)19 conducted a randomised, double-blind trial comparing two doses of IIV3 with 
placebo in HIV-infected children aged 6 to 59 months in South Africa. The per-protocol vaccine 
efficacy (culture and/or RT-PCR-confirmed symptomatic influenza) was not significantly different 
from placebo at 24·7% (95% CI -64·7, 66·4). This may, in part, be explained by the antigenic drift 
observed in the dominant circulating H3N2 strain.  Although the lack of efficacy could be explained 
by poor IIV3 immunogenicity in an HIV-infected population, the study was also underpowered. The 
required sample size of 420 to detect ≥50% reduction in influenza was based on an assumed attack 
rate of 20%, whereas the observed attack rate in placebo recipients was only 10%.  
 
Vaccine effectiveness (against RT-PCR-confirmed symptomatic influenza) of IIV3 in children aged 6 
months to 10 years was estimated from a test negative case-control study in Kenya.20 The study 
was undertaken during a 3-year period where the Kenya Medical Research Institute/Centers for 
Disease Control-Kenya and Kenyan Ministry of Health offered free influenza vaccine to children in 
two low-income rural and urban settings. Approximately 35% of all eligible children were 
vaccinated (2 doses IIV3 if aged <9 years). Patients attending with symptoms meeting pre-defined 
ALRI/ILI criteria were tested for influenza using RT-PCR. Controls were matched for age, date of 
sample and study site. Effectiveness estimates were controlled for the interval between symptom 
onset to sample collection. The combined results for the 3-year study found a vaccine effectiveness 
of 48·4% (95% CI 31·5, 61·2). The overall effectiveness was 50·2% (95% CI 24·9, 66·9) in 6 months 
to <5-year olds and 46·2% (95% CI 19·2, 64·2) in 5 to <10-year olds. The main limitations of the 
study are those inherent in the test-negative case control design, which include possible 
differences between those seeking health care for ALRI/ILI and the general population.  HIV testing 
was not routinely performed. 1% of subjects were known to be HIV-infected, with overall adult HIV 
prevalence 17% and 14% in the rural and urban setting respectively. Only medically-attended cases 
of ALRI/ILI were included, thereby missing community-managed cases. Nevertheless, this study 
provides the most robust IIV3 vaccine effectiveness estimates to date in African children and 
includes data from two diverse and economically deprived settings.  
 
Influenza vaccination in elderly adults 
Three studies have assessed the efficacy or effectiveness of influenza vaccines in elderly adults, all 
conducted in South Africa (Supplementary table 1).16-18 The two randomised trials16,17 were 
conducted in community-dwelling ambulatory adults ≥60 years, where approximately 70% of 
participants were white. Both trials included the use of LAIV, which is unlicensed for adults >49 
years in the USA, and thought to be less effective than IIV3 among elderly adults based on 
observational data.16 A  randomised, double-blind, placebo-controlled study16 showed LAIV 
efficacy against culture-confirmed symptomatic influenza of 42·3% (95% CI 21·6, 57·8), with 52.5% 
(95% CI 32·1, 67·2) efficacy against A/H3N2 strains and no efficacy against influenza B strains (-
10·1%, 95% CI -113·0, 42·7). Although the reason for the poor performance against vaccine-
matched influenza B strains is not clear, seroconversion to the influenza B vaccine component was 
lower than to A/H3N2 (figure 3). Vaccine efficacy was not significantly different between 
participants aged 60–69 years and those >70 years old.  
 
A  randomised, open-label trial compared the relative efficacy of IIV3 and LAIV in adults ≥60 years17 
against culture-confirmed symptomatic influenza. The study was powered on an assumed 
influenza attack rate of 8%, with non-inferiority between the two arms.  The incidence of influenza 
was much lower than expected at 0·9% in LAIV and 1·5% in IIV3 arms. As such, the study was 
significantly underpowered and no robust conclusions were possible. 
 
Finally, a retrospective nested case-control study in adults ≥65 years registered in a private medical 
funding organisation assessed influenza vaccine effectiveness against hospitalisation for acute 
respiratory conditions, non-elective cardiovascular disease, or all-cause death.18 Although not 
explicitly stated, participants presumably received IIV3, as to our knowledge LAIV was not available 
for routine clinical care in South Africa. Each case presenting with any of the primary endpoints 
were matched (by case identification date) to four randomly chosen controls from the same cohort 
and vaccination status ascertained from health records to calculate vaccine effectiveness. After 
adjustment for a number of confounders (e.g. comorbidities, age, gender), influenza vaccination 
was associated with a statistically significant reduction in the combined primary outcome 
measures by 19·3% (95% CI 3·1, 32·9) and all-cause mortality alone by 23·6% (95% CI 1·0, 41·0). 
However, a post hoc sensitivity analysis suggested that a healthy user bias in the likelihood of 
receiving influenza vaccine could potentially explain the vaccine effectiveness estimates seen.  
 
Influenza vaccination in other populations 
HIV-infected adults: 
In addition to the studies above including HIV-infected subjects, a double-blind, randomised, single 
centre, placebo-controlled trial of IIV3 in HIV-infected adults aged 18–55 years was performed in 
South Africa (Supplementary table 1).25 Participants had either been on first-line antiretroviral 
therapy (ART) for ≥3 months or were ART-naïve with a CD4+ count >100 cells/µl. Vaccine efficacy 
(against culture and/or RT-PCR-confirmed symptomatic influenza) was 75·5% (95% CI 9·2, 95·6) for 
all strains and a non-significant 73·3% (95% CI -1·2, 95·2) for vaccine-matched strains. No significant 
reductions in ILI or ARI was seen. The study was underpowered as 312 participants per study group 
were required to detect a 30% reduction in influenza, assuming an attack rate of 40% in the placebo 
arm. Only 255 and 251 participants were recruited to the IIV3 and placebo arms respectively and 
only 4·7% of placebo recipients developed influenza.  
 
Healthcare personnel: 
A prospective cohort study was carried out in healthcare personnel across five Kenyan hospitals 
(Supplementary table 1).26 Participants were asked about vaccination status during a monovalent 
pdm09H1N1 influenza vaccination campaign. The study controlled for month of follow up, gender, 
age, hospital location and contact with patients. The study failed to find an association between 
vaccination and reduced incidence of acute respiratory illness, work days missed, or RT-PCR-
confirmed influenza. As only 2/531 specimens tested detected pdm09H1N1, low circulating levels 
of pdm09H1N1 may explain the negative findings.  
 
Miscellaneous populations: 
Four test-negative case-control studies were identified from South Africa which estimate vaccine 
effectiveness across all age groups (Supplementary table 1).27-30 All originated from the same 
research team, using a network of general practitioners based in all provinces of South Africa (~90% 
within private healthcare centres). Patients presenting with an ILI had a throat and/or nasal swab 
tested for influenza by viral culture or RT-PCR. Influenza positive patients were classified as cases 
and influenza negative patients as unmatched controls. The first study estimated vaccine 
effectiveness between 2005 and 2009.27 Age-adjusted effectiveness was 48·6% (95% CI 4·9, 73·2) 
in 2005, -14·2% (95% CI -9·7, 34·8) in 2006, 12·0% (95% CI -70·4, 55·4) in 2007, 67·4% (95% CI 12·4, 
90·3) in 2008, and 29·6% (95% CI -21·5, 60·1) in 2009. Details of vaccine and circulating strain match 
are shown in supplementary table 1. The authors adjusted for age but no additional confounders. 
During 2009, the number of samples which each sentinel site could send was limited to five per 
week due to limited laboratory testing capacity. Sample selection was at the practitioner’s 
discretion, which could have introduced selection bias. McAnerney et al.29 estimated vaccine 
effectiveness between 2010 and 2013 and adjusted for age, underlying medical conditions and 
seasonality. Adjusted vaccine effectiveness was 54·2% (95% CI 2·4, 78·6) in 2010, 57·1% (95% CI 
15·5, 78·2) in 2011, 38·4% (95% CI -71·7, 78·1) in 2012 and 87·2% (95% CI 67·2, 95·0) in 2013. The 
vaccine effectiveness in 201428 and 2015,30 adjusting for age, underlying medical conditions and 
seasonality, was 43·1% (95% CI -26·8, 74·5) and 46·2% (95% CI -23·5, 76·5) respectively.  
 
The years of poor vaccine effectiveness were mainly related to antigenic drift resulting in vaccine 
and circulating strain mismatch, although small sample size in some years may also have 
contributed. As the data are from primary care settings, vaccine effectiveness against severe 
influenza is not included. Finally, as sentinel sites are private health care facilities where <20% of 
the South African population seek healthcare, the generalisability of these findings may be limited. 
 
Studies assessing immunogenicity of influenza vaccines 
Twelve studies were identified that evaluated influenza vaccine immunogenicity,11-13,15-
17,19,21,22,25,32,33 the majority of which focused on haemagglutination inhibition (HAI) titres, 
considered at present to be the gold standard immune correlate of protection following 
immunisation.35 This is, however, primarily true following IIV3 and not LAIV (which does not induce 
potent serum HAI responses), and where a clear correlate of protection is not yet established. 
Figure 3 shows Geometric Mean Fold Rise (GMFR) following vaccination for studies where this is 
reported or can be calculated .  
 
Two studies evaluated IIV3 immunogenicity in pregnancy.11,15 Pregnant women in South Africa 
mounted robust HAI titres following vaccination to all strains (Figure 3). In Mali, only HAI responses 
to pdm09H1N1 (HIV-negative women) are reported, which were higher than those seen to 
pdm09H1N1 in South African HIV-negative women (GMFR 14·9 vs 6·9). The mean age at enrolment 
was similar in the two studies (24·7 vs 26·2 years), but gestational age at enrolment was higher in 
Mali than in South Africa (32·6 vs 26·8 weeks). Pre-vaccination geometric mean titres (GMT) to 
pdm09H1N1 were 30·0 in South Africa and 20·9 in Mali. The reasons for this GMFR difference is 
unclear, but highlights the potential for variable responses in different African populations.  
 
Transfer of influenza-specific antibodies to infants following maternal immunisation and durability 
of this immunity was explored.11,13,15 In South Africa, HIV-unexposed children had higher HAI 
geometric mean titres (GMT) than HIV-exposed uninfected children to pdm09H1N1 (87·2 vs 48·2), 
H3N2 (41·4 vs 32·4) and influenza B (86·7 vs 50·0) at ≤7 days after birth. Both groups had 
significantly higher titres than placebo recipients. Follow up of the HIV-unexposed children in the 
first 6 months13 showed rapid waning of HAI GMTs to all antigens, with the proportion of children 
with HAI ≥1:40 dropping from 78·3% (pdm09H1N1), 56·6% (H3N2) and 81·1% (influenza B) at birth 
to 39·5%, 19·1% and 40% respectively by 16 weeks. Similar observations were found in Mali,15 
where HIV-unexposed children had HAI GMT to pdm09H1N1 of 141·6 at birth, 39·0 at 2-3 months 
and 33·7 at 4-5 months of age.  
 
The impact of helminths on IIV3 immunogenicity was evaluated in Gabon, in children aged 7 to 12 
years21 from rural and semi-urban settings. Although exact HAI titres are not provided, children 
from semi-urban settings had significantly higher HAI responses (H1N1 and influenza B) than those 
from rural areas. The presence of helminths was associated with poorer immunogenicity. A follow 
up study22 failed to show a significant effect of albendazole on HAI response to IIV3, although the 
study was powered for a much higher helminth burden than observed.  
 
Serum HAI increases following LAIV in elderly adults from South Africa were low, in keeping with 
previous studies of LAIV (Figure 3).16,17 HAI responses to IIV3 were lower in individuals aged ≥70 
years compared to those aged 60 – 69 years.17 The impact of HIV infection on IIV3 immunogenicity 
in both adults and children in South Africa is explored in three studies.11,19,25 HAI titre GMFR in 
HIV+ve pregnant women was <50% of the GMFR seen in HIV-ve pregnant women (2.9 vs 6.9, 2.4 
vs 6.0 and 3.2 vs 10.0 for pdm09H1N1, H3N2 and influenza B respectively, figure 3). Adults on ART 
had significantly higher seroconversion rates than ART-naïve patients to all antigens (Figure 3). HIV-
infected children aged 6 – 35 months had significantly lower seroconversion rates than those aged 
36 – 59 months to H3N2 (34·8% vs 70·6%), with similar trends for H1N1 (39·1% vs 58·8%) and 
influenza B (34·8% vs 47·1%). 
 
Two immunogenicity studies focused on antibody responses other than HAI.32,33 A study of healthy 
white South African students investigated anti-haemagglutinin and anti-neuraminidase antibody 
rises (single radial disc diffusion) following inactivated and live vaccines.32 Anti-haemagglutinin 
responses were observed in >60%  of individuals and were similar in all vaccine groups. Anti-
neuraminidase responses were identified in a greater proportion of inactivated vaccine recipients 
(p<0.05). The second study focused on Natural Killer cell responses to IIV3 in The Gambia.33 Anti-
IIV3 IgG concentrations were significantly boosted by vaccination in children (2-6 years old) and 
young adults (20-30 years old) but not in older adults (60-70 years old). 
 
Conclusions and future directions 
Our systematic review identified only 23 published studies evaluating efficacy, effectiveness or 
immunogenicity of influenza vaccines in Africa. As such, we did not exclude studies based on 
limitations in methodological design, to provide a complete picture of the available data. Due to 
the heterogeneity in study design, age group and vaccine type, a meta-analysis of these data are 
not possible. Several RCTs were underpowered, due to over-estimates of influenza attack rates, 
highlighting the importance of robust influenza incidence data to inform study design and sample 
size calculations. Improved influenza surveillance systems would help provide this, as well as a 
means to calculate vaccine effectiveness following influenza vaccine rollout.  
 
Other reasons why several studies failed to produce conclusive results include antigenic drift and 
unpredictability of dominant circulating strains each year. Estimating required sample sizes based 
on individual strain attack rates could avoid a loss of power due to antigenic drift, as it is unusual 
for all strains to drift significantly in one season. Quadrivalent vaccines containing both B-Yamagata 
and B-Victoria lineages should ideally be used to further minimise vaccine mismatch. 
 
No studies specifically addressed the impact of time of vaccination and influenza seasonality on 
vaccine performance. In contrast to temperate climates, countries in Africa experience year-round 
transmission or exhibit several peaks of transmission (some coinciding with rainy seasons).8,36,37 
Vaccine strategies such as biannual influenza vaccination need further consideration.38 As the 
timing of vaccine availability is currently dictated by requirements for temperate countries, more 
data are required on the suitability of these vaccine formulations for contemporaneous strains in 
the tropics.  
 
Several other factors likely to effect influenza vaccine performance were under-represented. 
Placental malaria infection and maternal hypergammaglobulinaemia  are known to effect placental 
antibody transfer9 and the impact of these conditions on maternal immunisation strategies should 
be studied. The impact of factors such as HIV, malnutrition and TB also require further study to 
understand the effect on influenza vaccination. While it is difficult to draw firm conclusions about 
the relative effectiveness of influenza vaccines in HIC and LMIC from the data currently available, 
the most comprehensive effectiveness data (from South Africa)27-30 shows a similar range when 
compared with USA effectiveness data from the same years (Appendix).39  
 
Our review also highlights the need to obtain data from a broader range of African populations, 
with 16 of the 23 studies performed in South Africa. Even within these studies, several were 
performed in groups that may not be representative of the wider socioeconomic makeup in the 
country. Given the genetic and environmental heterogeneity across Africa, further studies to 
explore any regional variation in vaccine efficacy are important. Studies should include 
immunogenicity measures to provide insight into any findings observed. While some studies we 
identified measured serum HAI to assess IIV3 immunogenicity, LAIV studies should include 
measures of mucosal antibody and systemic T-cell responses as LAIV likely protects via multiple 
mechanisms. Our own ongoing study of LAIV in Gambian children (NCT02972957) hopes to shed 
light on the reasons for the poor LAIV efficacy in Senegal.24  
 
The majority of studies used laboratory-confirmed influenza illness as a primary outcome and no 
strong conclusions could be drawn for severe outcomes such as hospitalisation, medically-
attended pneumonia or mortality. These outcomes are important for policy decisions on the 
implementation of future influenza vaccine programmes40 and demonstration of mortality benefit 
following vaccination is a criterion for GAVI investment.41 The reduction in all-cause ALRI and 
severe infant pneumonia following maternal immunization in South Africa is encouraging but 
clearly more data are required.14,31  
 
The only two studies of LAIV efficacy in African children have provided dramatically contrasting 
results.23,24 It is possible that the recent lack of efficacy in Senegal seen is unique to the 
pdm09H1N1 strain and simply mirrors the poor effectiveness of LAIV against pdm09H1N1 
observed in the USA.42 If ongoing efforts to improve this LAIV component are successful, further 
RCTs would be warranted in African populations given the greater efficacy of LAIV seen in children 
when compared to IIV3 in previous studies.43,44 Furthermore, lower manufacturing costs compared 
to IIV3 (partly as less antigen is required therefore allowing more doses per egg) and less need for 
trained healthcare personnel to deliver an intranasal vaccine make LAIV particularly suitable in 
Africa. The potential for successful LAIV rollout to provide indirect benefit by reducing transmission 
to unvaccinated vulnerable populations (shown recently in the UK)45 should also be assessed.  Data 
are also not available on how best to immunise 6 months – 2-year old children, an age group that 
responds poorly to IIV3 and are outside the licence for LAIV use. The results are awaited of a safety 
and immunogenicity study comparing MF59TM-adjuvanted IIV3 with standard IIV3 (NCT01819155) 
in Senegalese children aged 6 to 71 months.  
 
The lack of any robust IIV3 efficacy data in the elderly is striking. Even in HIC, standard IIV3 are only 
modestly immunogenic due to immunosenescence.46 The use of MF59-adjuvanted IIV3 and high 
dose IIV3 have emerged as two strategies to enhance the immunogenicity and efficacy of influenza 
vaccines in this high-risk group.47,48 To our knowledge, there are no ongoing studies of these 
vaccines in Africa and should be the focus of future studies in elderly populations. With the 
increasing burden of cardiovascular disease in LMIC, the potential for influenza vaccination to 
prevent stroke and heart disease is also important to consider. An ongoing multicentre RCT of 
influenza vaccine to prevent adverse vascular events (RCT-IVVE, NCT02762851) aims to include 
adults aged ≥18 years from several African sites with study completion estimated in 2020. Another  
benefit of influenza vaccination may be reduction of pneumococcal pneumonia. The importance 
of influenza in the pathogenesis of pneumococcal pneumonia was demonstrated by the reduction 
of virus-associated pneumonia in an RCT of Pneumococcal Conjugate Vaccine (PCV) in South 
African children.49 Furthermore, the reduction in all-cause infant ALRI following maternal 
immunization, despite negligible influenza detection in placebo recipients, supports an impact of 
influenza vaccination on reducing bacterial pneumonia.14 An RCT of combined influenza vaccine 
and PCV in several high risk groups would be valuable, especially in the context of increasing 
pneumococcal disease due to non-vaccine serotypes.  
 
The lower immunogenicity of IIV3 in HIV-infected patients in HIC is also reflected in the few studies 
from Africa, although due to the increased susceptibility to influenza in these individuals, the 
benefits of vaccination are greater. As ART-treated individuals mount higher immune responses to 
IIV3 than ART-naïve patients, increasing ART rollout could improve vaccine performance. With the 
high burden of HIV infection in many African countries, new vaccine strategies to enhance 
immunogenicity are required, for example, the use of high-dose or adjuvanted vaccines. Results 
are awaited from a systems vaccinology study of IIV3 in HIV-infected individuals in Uganda 
(NCT01916759) that may provide mechanistic insight into how best to do this. Such studies are 
important in informing rational design of new vaccines suited to the population in need.  
 
The most robust data available at present to guide influenza vaccination programmes is in 
pregnant women. Two RCTs11,15 have demonstrated the efficacy of IIV3 in reducing influenza in 
pregnant women and their infants, although for the latter group, vaccine efficacy was only 
significant in HIV-unexposed infants. Protection for infants via maternal immunisation is especially 
important given the high influenza-related morbidity and mortality in infants <6 months50 and the 
lack of a licensed vaccine in this age group. Nevertheless, both serum HAI and efficacy waned 
rapidly by four months of age, so alternative strategies are required to increase titres in pregnant 
women and durability of infant protection. Future studies will additionally need to focus on the 
cost-effectiveness, feasibility and acceptability of maternal immunisation in line with the 
deliberations for other vaccines applicable in pregnancy. A recent analysis in Mali showed that such 
a programme would be cost-effective in most settings if vaccine can be obtained, managed and 
administered for ≤$1·00 per pregnant woman.51 Ideally health economic analyses should take into 
account a wider range of potential benefits: impact on bacterial pneumonia, indirect benefits due 
to reduced transmission, impact on antibiotic use,52 although more data are required to inform 
these aspects. Furthermore, as the burden of influenza is high in Africa, even imperfect vaccine 
effectiveness can lead to a greater number of absolute cases prevented and significant public 
health benefit. Finally, as countries in Africa establish influenza immunisation programmes, it is 
vital that this is done alongside increased capacity for influenza surveillance, so ongoing vaccine 
effectiveness can be monitored over time.  
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Figure legends 
 Figure 1: Study selection process 
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 Figure 2: Forest plot of influenza vaccine efficacy (a) and effectiveness (b). *Vaccine efficacy 
estimates are per-protocol with the exception of Madhi et al 2011 which reports intention to 
treat. CI: Confidence interval; IIV3: Trivalent inactivated influenza vaccine. LAIV: Live attenuated 
influenza vaccine; HIV: Human immunodeficiency virus 
 
 Figure 3: Summary of serum Haemagglutination Inhibition assay geometric mean fold rise 
following influenza vaccination in African populations. ART: Antiretroviral therapy. IIV3: 
Trivalent inactivated influenza vaccine. LAIV: Live attenuated influ-enza vaccine; HIV: Human 
immunodeficiency virus; GMFR: Geometric fold rise; gp: Group. 
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Table 1 – Characteristics of included studies. IIV3: Trivalent inactivated influenza vaccine; 
LAIV: Live attenuated influenza vaccine 
Country South Africa: 16 
Mali: 1 
Kenya: 2 
Gabon: 2 
Senegal: 1 
Gambia: 1 
Study design Randomised trial: 12 
Case-control: 6 
Cohort: 1 
Other: 4 
Study population Maternal immunisation: 6 
Elderly: 3 
Children: 6 
Other: 8 
Vaccines IIV3: 17 
LAIV: 3 
IIV3 & LAIV: 2 
Monovalent inactivated: 1 
